Chinese biopharmaceutical company Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has announced the appointment of Dr. Rafael G. Amado as President and Global Head of Cancer Research and Development (R&D), effective December 30, 2022. Dr. Amado will join the company’s management committee as a core member, reporting directly to Dr. Du Ying, the founder, chairman, and CEO of Zai Lab.
Dr. Amado’s Background and Experience
Dr. Amado brings extensive experience in cancer research and development to Zai Lab. Most recently, he served as Executive Vice President, Head of R&D, and Chief Medical Officer (CMO) at Allogene Therapeutics, Inc. Prior to that, he held the position of Senior Vice President and Global Head of Cancer R&D at GlaxoSmithKline. Dr. Amado also worked as Executive Director of Cancer Clinical Research and Global Development at Amgen.
Dr. Amado received his Doctor of Medicine from the University of Seville School of Medicine in Seville, Spain. He completed his internship and residency training at Michael Reese Hospital and Medical Center, and his hematology/oncology specialist training at UCLA.
Impact on Zai Lab’s Cancer R&D Strategy
The appointment of Dr. Amado is expected to significantly enhance Zai Lab’s capabilities in cancer research and development. His extensive background in oncology and leadership roles at major pharmaceutical companies will provide valuable insights and strategic direction for Zai Lab’s ongoing and future cancer – related projects. As the company continues to expand its pipeline and focus on innovative therapies, Dr. Amado’s expertise will be instrumental in driving Zai Lab’s mission to improve patient outcomes in cancer treatment.-Fineline Info & Tech
